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Two well-known hallmarks of cancer are the abilities to sustain proliferation and invade 
surrounding tissue, and pathways involved in these processes have been scrutinized for 
possible therapeutic targets in recent years. Since its discovery, Ki-67 has been intimately 
linked to the cell cycle and widely accepted as a marker for the growing fraction of cells 
in a tumor sample, and more recently its potential as a prognostic and predictive marker 
for various cancers has been explored. Despite the wide use of Ki-67 in the clinical and 
pathological setting, little is known about its actual function and role as a potential 
therapeutic target for cancer. To better characterize Ki-67’s function to optimally exploit 
this gene/protein for prognostic, predictive, and therapeutic purposes, we created isogenic 
Ki-67 knockout cells in a “normal” and cancer cell line. Unlike previous efforts to 
knockdown Ki-67, we were able to generate multiple independent Ki-67 knockout clones 
in two cell lines that definitively lacked functional full length Ki-67 protein. In colony 
formation assays in vitro and tumorigenic assays in vivo, the knockout clones displayed a 
reduced proliferative and clonogenic potential, illustrating how inhibition of Ki-67 could 
result in a decreased ability of cancer cells to invade and colonize surrounding and distant 
tissue. A current model of metastasis maintains that cancer stem cells (CSCs) are required 
to establish tumor formation at distant sites, and in colorectal cancers, those CSCs are 
often identified by the expression of cell surface markers CD133 and CD44. The 
knockout clones had a markedly reduced CD133+CD44+ population of cells compared to 
the parental cell line, demonstrating that loss of Ki-67 resulted in fewer colonies and 
tumors by decreasing the “stemness” of the cells. CSCs are known to be resistant to 
various chemotherapies, but we found that the loss of Ki-67 in the cancer cell line 
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resulted in sensitization to multiple chemotherapeutic agents. These findings combine to 
establish that Ki-67 is a viable therapeutic target, particularly in the metastatic setting. By 
specifically inhibiting Ki-67, it could be possible to greatly decrease the risk of 
micrometastatic disease that is often times refractory to standard therapy. 
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One of my favorite speeches comes from Michael Lewis, the author of “The Blind Side,” 
when he gave the commencement address at Princeton University’s 2012 Baccalaureate, 
and it seems particularly pertinent at this juncture in my life.  
 
“People really don’t like to hear success explained away as luck – 
especially successful people. As they age, and succeed, people feel 
their success was somehow inevitable. They don’t want to 
acknowledge the role played by accident in their lives…Don’t be 
deceived by life’s outcomes. Life’s outcomes, while not entirely 
random, have a huge amount of luck baked into them. Above all, 
recognize that if you have had success, you have also had luck – 
and with luck comes obligation. You owe a debt, and not just to 
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moving to Baltimore, and to say that I left begrudgingly would be a huge understatement. 
However, I am very lucky that events outside my control steered me to Johns Hopkins so 
that I would have the opportunity to work with and learn from my advisor, Ben Ho Park. 
Not only is he one of the most unassumingly intelligent people I have ever met, but he is 
also exceedingly generous and caring as well. His charisma, sophomoric sense of humor, 
and eternal optimism give him such a warm and disarming quality that it is impossible to 
not want him as your boss and, more importantly, your friend. Thank you, Ben, for 
becoming my extended Baltimore family and teaching me far more than breast cancer 
genetics. If the old adage is true that good things happen to good people, then I expect 
nothing but the very best for Ben. 
 
I am beyond lucky to be the son of Roslyn Melia and Leonard Cidado. To feel the 
amount of love and pride they have for me every day is inspiring and humbling. Always 
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encouraging of whatever endeavor I undertook, they never expected anything of me other 
than my best effort. My drive to succeed in the classroom or workplace, to be the best 
man possible, and to be happy in life has always been my attempt at repayment for all the 
opportunities afforded to me by the many sacrifices made by them along the way. But 
perhaps the best way to honor everything my parents have given me is to now do the 
same for my daughter so that she may one day feel so incredibly loved that anything is 
possible, including getting a Ph.D. Mom and Dad, thank you for being the models of hard 
work, sacrifice, compassion, generosity, and love that has led me to this point in my life 
where I can say that I am truly happy. 
 
And finally, my wife, Melissa Cidado. My time in Baltimore would have seemed more 
like an extended and arduous business trip if she wasn’t by my side. But instead, we’ve 
made it our home over these past 5 ½ years. In that time, we got married, adopted our 
first dog, and gave birth to our first child. It would have been very easy for her to not 
leave Boston, to not uproot her life, to not leave her friends and her job. But she decided 
to come with me. It would have been very easy for her to resent our time here, but instead 
she embraced our situation and even earned her MBA from Johns Hopkins Carey 
Business School. So now we have two Hopkins alumni in the family! She made all those 
sacrifices so that I may pursue my goals. I am so incredibly lucky to have such a 
wonderful, ambitious, selfless, loving, and supportive woman by my side. Each hurdle 
that life puts in my path is that much lower knowing that she’s on this journey with me. 
And each light at the end of the tunnel is that much brighter. I don’t know what 
adventures lay ahead of us, but I do know that I’m excited to experience every one of 
them with her. Mel, you, Avery, and Calla are the reasons any of this is worth doing and 
the best parts of each and every day. Thank you for making all of this possible. 
 
As you can see, there is no way I deserve the amount of love and support I’ve received 
from these amazing people over the years. I am just unimaginably lucky.  
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Understanding the basic mechanisms of cell proliferation has led to major insights and 
advances in physiology and medicine. For cancer research, however, the identification of 
genes and proteins that are potential targets for therapy is an ongoing quest. Recently 
there has been interest in targeting Ki-67 for cancer therapy given the fact that aggressive 
cancers express this protein at high levels while quiescent cells show a complete absence 
of Ki-67 protein [1–3]. Although there is conflicting data regarding the expression level 
of Ki-67 in normal dividing cells [4, 5], Ki-67 expression has become the accepted 
marker for determining the growing fraction of cells in histopathological samples, 
particularly human neoplasms [6]. 
Ki-67 was originally identified by Gerdes et al. in 1983 as a monoclonal antibody 
that reacted with nuclei of the Hodgkin’s lymphoma cell line, L428 when injected into 
mice [7]. They then discovered that the antibody reacted similarly against a variety of 
 
 
other human cancer cells but not against normal peripheral blood lymphocytes and 
monocytes. Likewise, when the group chemically induced differentiation of HL-60 cells 
to mature macrophages and stained with Ki-67 at various intervals, expression of Ki-67 
was increasingly suppressed. This led them to believe Ki-67 could be a “potent tool for 
easy and quick evaluation of the proportion of proliferating cells in a tumor.”  
 
GENE STRUCTURE, CELLULAR LOCALIZATION, and PROTEIN DOMAINS 
It was still another decade before Ki-67 was characterized as a large nuclear protein 
through cloning and sequencing of a cDNA library [8, 9]. Schluter et al. determined the 
complete nucleotide and predicted amino acid sequences, identifying 15 exons that 
correspond to two predominant splice isoforms of the Ki-67 gene (now known as MKI67, 
located on 10q26). These two isoforms correspond to open reading frames of 9,768 and 
8,688 base pairs that encode for proteins with calculated molecular weights of 360 and 
320 kD, respectively. The difference between the two splice isoforms was the absence of 
exon 7 from the smaller transcript. But their most intriguing finding was that 6,845 base 
pairs of the open reading frame all lay within exon 13, which contained 16 repetitive 
elements, each 122 amino acids in length that share 43 – 62% homology. Within these 
“Ki-67 Repeats” was a highly conserved stretch of 22 amino acids, known as the “Ki-67 
Motif,” that shared 72 – 100% identity and comprised the epitope recognized by the Ki-
67 antibody. In the same study, they also identified multiple PEST sites, regions rich in 
proline, glutamic acid, serine, and threonine that purportedly designate the protein for 
rapid proteolysis. This aligns with previous findings that Ki-67 is rapidly degraded after 
mitosis, with a half-life of about 1 – 1.5 hours [10, 11]. 
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Detailed cell cycle analysis revealed that Ki-67 localizes to distinct regions of the 
nucleus during all active (non-G0) stages of the cell cycle [12–17]. During interphase and 
early-G1 phase, Ki-67 protein is primarily organized around heterochromatic, satellite 
DNA regions, such as the centromere and telomeres [17]. Then as the nucleoli begin to 
reassemble during mid-to-late-G1 phase, Ki-67 can be found localized in those structures. 
The nucleolus is comprised of three elements: the fibrillar center (FC), the dense fibrillar 
component (DFC), and the granular component (GC). The processing of ribosomal RNA 
(rRNA) and associated proteins occur in these areas, progressing from the DFC to the GC 
[18, 19]. However, Ki-67 does not appear to be involved in the assembly of ribosomes 
since it does not co-localize with fibrillarin, a highly conserved nucleolar protein 
associated with small nucleolar RNAs (snoRNAs) and involved in the assembly of 
ribosomes in the DFC [20]. Therefore, it is accepted that Ki-67 localizes to the 
“fibrillarin-deficient” region of the DFC. During S phase, Ki-67 expression begins to 
increase, with protein levels peaking during metaphase and gradually decreasing 
thereafter [13, 15, 21, 22]. It has been observed that Ki-67 is concentrated around the 
nucleolar foci during this time while also somewhat present in the nucleoplasm [15, 16, 
21, 22]. As the cell transitions into mitosis, Ki-67 disperses from the dissociating nucleoli 
to the condensed chromosomes and chromosomal periphery [14]. This is also the only 
time when Ki-67 is reported to be detectable in the cytoplasm [23]. Toward the end of 
mitosis, Ki-67 is once again localized around nuclear structures, likely the 
heterochromatic regions, as the cell progresses toward the next G1 phase. 
Studies have shown that these spatial and temporal expression patterns are 
regulated by cell cycle-specific, post-translational modifications [23–25]. In particular, 
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these groups demonstrated that Ki-67 is phosphorylated by the CDK1/Cyclin B complex 
during mitosis. This evidence was confirmed both in vitro and in vivo, which included the 
binding of these phosphorylated forms of Ki-67 with the monoclonal MPM-2 antibody. 
The MPM-2 antibody recognizes a mitosis-specific phosphorylated epitope that is present 
in a number of different proteins that are active during mitosis [26–28]. There is evidence 
that many of the phosphorylated MPM-2 antigens are required for the onset of mitosis 
and that dephosphorylation of those epitopes is necessary for exit of mitosis. So the 
discovery that Ki-67 is recognized by the MPM-2 antibody at the beginning but not the 
end of mitosis demonstrates that phosphorylation likely regulates the function of Ki-67 
during mitosis [24]. 
In 1995, Hofman and Bucher identified a forkhead-associated domain (FHA) in 
twenty seemingly unrelated proteins through advanced sequence profiling methods. One 
of those proteins was Ki-67 [29]. Upon further inspection, they found that most of those 
identified proteins also contain a nuclear localization signal and are involved in cell cycle 
regulation. More recent studies have revealed that these FHA domain-containing 
regulatory proteins, kinases, phosphatases, and transcription factors play crucial roles in 
cell growth and signal transduction, particularly in relation to the DNA damage response. 
Unlike other signal transduction domains that recognize phosphoproteins, the FHA 
domain is the only one that is phosphothreonine (pThr)-specific whereas most others 
recognize both pThr and phosphoserine (pSer). Despite the specificity for the pThr 
residue, the surrounding sequence motifs recognized by the FHA domain are quite 
diverse and completely dependent upon the particular FHA-containing protein [30, 31]. 
Through yeast two-hybrid screenings, the human kinesin-like protein 2 (Hklp2) and the 
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putative RNA-binding human nucleolar interacting with the FHA domain of Ki-67 
(hNIFK) were identified as interacting partners with the FHA domain of Ki-67 [32, 33]. 
Both proteins were also able to interact with GST-FHA(Ki-67) fusions, especially after 
the proteins were phosphorylated with cyclin/cyclin-dependent kinase complexes. Hklp2 
(also known as Kif15) participates in the assembly and stabilization of the bipolar 
spindle, localizing to the chromosome through Ki-67 [34–36]. In fact, when Ki-67 was 
silenced with siRNAs, Hklp2 failed to localize to the chromosomes, resulting in much 
longer bipolar spindles. Combined with the detailed cell cycle analysis and localization 
studies, it is likely that Ki-67 plays a role in the progression of the cell cycle through the 
dynamic interactions of its FHA domain with other cell cycle-related proteins. 
A third predicted protein domain was identified in 2002 by Scholzen et al [37]. 
They found that the last 220 amino acid residues of the C-terminus of Ki-67 could bind to 
all three mammalian heterochromatin protein 1 (HP1) isoforms through a series of co-
immunoprecipitation and yeast two-hybrid assays. Specifically, through 
immunofluorescence assays, they found that Ki-67 co-localized with HP1 during 
interphase of cell cycle. HP1 is a small, non-histone chromosomal protein identified as a 
component of heterochromatin that acts as a dosage-dependent modifier of position effect 
variegation [38, 39]. All three isoforms consist of two highly conserved domains: the N-
terminal chromodomain (CD), which recognizes methylated histone H3K9 for chromatin 
binding, and a C-terminal chromoshadow domain (CSD) that is thought to be responsible 
for protein-protein interactions. This interaction with the gene-poor, repetitive, 
transcriptionally inert, and late-replicating heterochromatic regions of the genome lend a 
wide range of functions for the HP1 proteins. Amongst these are transcription silencing 
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and activation [40–43], telomere capping and silencing [44], DNA replication and repair 
[45, 46], and mitosis [47, 48]. Although the functional significance of the interaction 
between Ki-67 and HP1 has not yet been clarified, it is believed that Ki-67 could be 
responsible for or involved in higher order chromatin structure. 
The association of Ki-67 with mitotic chromosomes, HP1 proteins, and the 
kinesin-like Hklp2 protein, along with its spatial and temporal expression patterns lead 
many to speculate that Ki-67 is integrally involved in cell growth and division. 
Consequently, many believe that Ki-67 is an essential gene/protein, vital to the survival 
of the cell, leading a few groups to use functional genomics approaches to interrogate this 
hypothesis. 
 
FUNCTIONAL GENOMIC STUDIES 
Since Ki-67 is highly expressed in proliferating cells, various groups have tried using 
some form of RNA interference (RNAi) to silence or knock down the expression of 
MKI67 in hopes of determining the effect on cell viability and cellular processes, 
particularly whether Ki-67 could be a viable therapeutic target in a number of cancers. 
The first study was conducted by Duchrow et al. and used antisense-RNA (asRNA) and 
recombinant protein to silence MKI67 expression. They reported an overall slower 
incorporation of BrdU into cells and progression through the cell cycle [49]. Another 
group published three separate studies, all utilizing antisense oligonucleotides (asRNA) 
to knock down MKI67 expression. They did so in various cancer cell lines as well as in 
vivo models of bladder cancer, prostate cancer, and renal cell carcinoma. They observed 
decreased MKI67 transcript and protein expression, inhibited cell growth, and increased 
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apoptosis in monolayer and 3-D culture after treatment with the asRNA. Similary, the 
xenograft tumor volumes were significantly inhibited in the antisense-treated mice [50–
52]. And much like the previous group, Zheng et al. published four different studies 
where they knocked down MKI67 expression using peptide nucleic acids (PNAs), small 
interfering RNAs (siRNAs), or short hairpin RNAs (shRNAs), noting a marked reduction 
in cell proliferation and increase in apoptosis [53–56]. For many people, these studies 
represent further proof that Ki-67 is vital for cell growth and proliferation. But given the 
caveats that accompany RNAi experiments, such as knockdown efficiency and 
specificity, it is difficult to make any definitive conclusions. 
 
CLINICAL UTILITY 
In the clinical setting, Ki-67 is one of a number of biomarkers frequently used as 
prognostic indicators for early breast cancers (EBCs) [57, 58]. It can be measured using 
one of two approaches: a semi-quantitative analysis of MKI67 mRNA extracted from 
frozen or formalin-fixed paraffin embedded (FFPE) tissue, or a score based on the 
percentage of cancer cells that stain positively for Ki-67 protein by 
immunohistochemistry (IHC). One study reports a strong linear correlation between the 
two methods when assessing a panel of 53 breast cancers. However, IHC staining has a 
number of advantages, like the ability of the pathologist to exclude contaminating non-
cancer cells. It is also less costly and more accessible in a routine diagnostic laboratory. 
As expected, Ki-67 staining strongly correlates with tumor grade since mitotic 
index is one of the three grading components [59, 60]. Despite evidence from early 
studies that Ki-67 is a reliable single prognostic indicator, its use as a stand-alone marker 
7 
 
has become controversial [61, 62]. There are some studies that claim Ki-67 can be used 
as a single biomarker for both relapse prognoses and predictions for therapeutic response. 
Others have reported that Ki-67 is neither prognostic nor predictive [62], prognostic but 
not predictive [61][63], or prognostic only as an on- or post-treatment intermediate 
biomarker [64, 65]. A contributing factor to the disparity amongst these meta-analyses is 
a lack of established Ki-67 staining, scoring, and reporting protocols. Attempting to 
harmonize methodologies in order to validate clinical applications of Ki-67 assessment, 
the International Ki-67 in Breast Cancer Working Group published a number of 
recommendations for standardized Ki-67 evaluation [66]. 
Despite the potential shortcomings of Ki-67 as a single prognostic and predictive 
indicator, its incorporation as one of multiple genes in the Oncotype DX assays has led to 
its use in both a prognostic and predictive setting for estrogen receptor (ER) positive, 
node negative, tamoxifen treated, early breast cancers (EBCs) [67–69]. Similar Oncotype 
DX assays are also available for prostate and colon cancers. Since roughly 60 – 75% of 
women with EBC are needlessly treated with adjuvant chemotherapy and exposed to the 
associated risks, better methods are needed to stratify patients into groups of low, 
intermediate, and high risk of recurrence so that better informed treatment decisions can 
be made. The Oncotype DX breast cancer assay evaluates the expression level of 21 
genes (16 cancer-related genes and 5 reference genes), of which one is MKI67, known to 
be associated with tumor proliferation, invasion, and estrogen signaling [70]. This 
expression data is combined with clinical-pathological data into an algorithm that 
determines a 10-year distant recurrence score that can help predict chemotherapy benefit. 
Therefore, the greater the level of MKI67 expression along with other genes, the worse 
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the prognosis and the higher likelihood of recurrence [71]. According to current 
American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer 
Network (NCCN) guidelines, and until the full results of the TAILORx clinical trial is 
reported, within the context of Oncotype DX, MKI67 and other genes can serve as a 
reliable predictive indicator of response to chemotherapies.  
 
HYPOTHESIS 
Despite the utility of Ki-67 as a proliferation marker for clinical-pathology samples and a 
prognostic and predictive indicator for various cancers, a current unmet need is the lack 
of clarity regarding its function, which will be necessary for validating Ki-67 as a true 
target for cancer therapy. The fact that Ki-67 is such a large protein and extremely 
sensitive to protease cleavage makes it extremely difficult to use in biochemical assays, 
which likely has led to the uncertainty surrounding its molecular mechanism [9, 72]. Also 
contributing to the lack of information regarding Ki-67 is the limited capacity of past 
technologies to completely abrogate its function, highlighted by the few aforementioned 
functional genomic studies utilizing various forms of RNA interference (RNAi) to knock 
down MKI67 expression in various cancer cell lines. While each reports moderate 
knockdown efficiency that correlates with reduced cell proliferation and increased 
apoptosis, lending further credence to the belief that Ki-67 is an integral protein in the 
regulation of cell division and survival [2, 50, 55, 56], none conclusively demonstrate the 
involvement of Ki-67, either through rescue experiments or the use of multiple RNAi 
sequences. In this study, we investigate the role of Ki-67 in cell proliferation and tumor 
initiation by utilizing gene targeting to create mutant Ki-67 knockout human somatic cell 
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lines that ablate all functional Ki-67 protein. Since it has been reported that some 
dividing cells did not stain for Ki-67, we expect that knock out of Ki-67 will not affect 

















Cell culture conditions 
MCF-10A [73] and its derivative cells were grown in DMEM:F12 medium (Invitrogen) 
supplemented with 5% horse serum (HS, Hyclone), 20ng/mL epidermal growth factor 
(EGF, Sigma), 10µg/mL insulin (Sigma), 0.5µg/mL hydrocortisone (Sigma), 0.1µg/mL 
cholera toxin (Sigma), and 1% penicillin/streptomycin (Invitrogen). This is referred to as 
“standard growth” media. For “physiologic EGF” conditions, we use standard growth 
media but replace 20ng/mL EGF with 0.2ng/mL EGF. For EGF-free, “growth arresting” 
conditions, phenol red-free DMEM:F12 medium and 1% charcoal dextran-treated FBS 
(CD) were used in place of the standard medium and serum, respectively. This is referred 
to as “growth arrest” media. Standard growth media for DLD-1 and its derivative cells 
was McCoy’s 5A medium (Invitrogen) supplemented with 5% fetal bovine serum (FBS, 
Hyclone) and 1% penicillin/streptomycin. All cells were maintained in a 37oC incubator 




Targeted knock out of MKI67 
Targeting vectors were designed as previously described [74, 75]. Briefly, homology 
arms were PCR-amplified from MCF-10A genomic DNA (gDNA) and ligated into the 
promoterless gene-targeting vector pSEPT. The homology arms and intervening 
neomycin selection cassette (consisting of splice acceptor, IRES, neo ORF, 
polyadenylation signal, and flanking loxP sites) was then subcloned into an adeno-
associated virus (AAV) vector backbone. After packaging in HEK-293T cells, targeting 
vectors were transduced into MCF-10A or DLD-1 cells, and antibiotic selection was 
performed using 120µg/mL and 500 µg/mL of G418 (Invitrogen), respectively. 
Neomycin-resistant colonies were expanded and screened for homologous integration of 
the targeting vectors via our previously described PCR-based method [76]. Single-cell 
clones were then infected with an adenovirus encoding Cre recombinase to remove the 
selection cassette, followed by single-cell dilution and screening by PCR to confirm 
successful Cre recombination. Cloning and screening primers are listed in Table 1.  
 
Quantitative real-time, reverse transcription PCR (qRT-PCR) 
Total RNA was prepared from cells using RNeasy Plus kit (Qiagen). cDNA was 
synthesized with a First-Strand cDNA Synthesis kit (GE Biosciences). PCR amplification 
was done using the MyIQ system (BioRad) with Platinum Taq polymerase and SYBR 
green dye (Invitrogen). Please refer to Table 1 for primer sequences. Human MKI67 





Proliferation and chemotherapy assays 
MCF-10A isogenic cells were seeded at least in triplicate at 1x103 cells per well in solid 
black 96-well plates (Corning) in growth arrest media conditions overnight. The media 
was changed the following day to either standard growth or growth arrest media for the 
duration of the experiment. DLD-1 isogenic cells were seeded in the same manner, 
except standard growth media was used throughout. On specified days, cell viability was 
assessed by CellTiter-Glo according to manufacturer’s protocol. For proliferation assays 
in the presence of chemotherapeutic agents, cells were plated in the same manner. The 
day after cell seeding, which was considered Day 0, 5-Fluorouracil (5-FU, Sigma), 
Paclitaxel (Sigma), Cisplatin (Sigma), and Doxorubicin were added to the appropriate 




The isogenic MCF-10A and DLD-1 cells were plated at either 2.5x102 or 1x103 cells per 
well in 6-, 12-, 24-, and 48-well plates in standard growth media. The cells were allowed 
to form colonies for 10 days before being fixed and stained with 0.2% crystal violet (w:v) 
in 10% buffered formalin. All colonies visible by eye were counted. 
 Single cell clonogenic assays for MCF-10A and DLD-1 cells were plated in five 
96-well plates per clone at a density of 0.5 and 1.0 cells/well, respectively, in 175µL of 
standard growth media. Clonogenicity is scored by counting the number of wells with 
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colonies per plate per clone, and relative colony size was also documented. MCF-10A 
cells were scored after two weeks and DLD-1 cells were scored after three to four weeks. 
 For colony formation assays in semisolid medium, 1x102 or 1x103 exponentially 
growing cells were cast in 400µL of top layer medium composed of 2% GelTrex LDEV-
Free Reduced Growth Factor Basement Membrane (Gibco) in standard growth medium 
and poured on top of 100µL pure GelTrex LDEV-Free Reduced Growth Factor Basement 
Membrane in 8-chamber tissue culture treated glass slide (BD Falcon). Media plus 
basement membrane mixture was replace every four days until the colonies were 
visualized and photographed after ten days of incubation.  
 
Cell line immunohistochemical and western blot analysis 
Cell line paraffin-embedded blocks were prepared from exponentially growing or fully 
arrested cells in T75cm2 flasks. MCF-10A cells were cultured in either standard 
(20ng/mL EGF, 5% HS) or growth arrest (0ng/mL EGF, 1% CD serum) conditions. Two 
flasks worth of cells were cultured for each clone. The cells from both flasks were 
combined following dissociation with trypsin, spun down for 5 minutes at 600 x g, 
washed twice with HBSS, and centrifuged again. The pellets were resuspended and fixed 
for 18 hours at benchtop in 10mL 10% buffered formalin, washed twice in PBS, and 
resuspended in cold PBS (100µL total). An agarose plug was prepared for each clone by 
mixing 100µL 2% agarose (w:v) with the resuspended cell pellet, after which the plugs 
were arrayed in a cassette, paraffin embedded, and processed for 4µm-thick slides. For 
immunohistochemical labeling, the slides were deparaffinized in xylene for 30 minutes 
and rehydrated using graded ethanol concentrations. Following antigen retrieval, labeling 
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of Ki-67 (7B11, Invitrogen) was performed using the avidin-biotin peroxidase complex 
technique and 3’, 3’-diamino-benzidine (DAB) as chromogen (Ventana/Biotek 
Solutions).  
Whole-cell protein lysates were prepared from exponentially growing cells in 
T75cm2 flasks. DLD-1 cells were propagated in standard growth conditions while MCF-
10A cells were grown under 20ng/mL EGF and 1% CD serum. Cells were dissociated 
with trypsin for 10 minutes (0.25% Trypsin-EDTA, Invitrogen), resuspended in standard 
growth media, and spun down for 5 minutes at 600 x g. The cell pellets were resuspended 
in 150µL PBS (Invitrogen) supplemented with protease inhibitor (Roche Complete Mini). 
Then 150µL 2X Laemmli sample buffer (Sigma) supplemented with protease inhibitor 
was added, mixed thoroughly, and boiled for 10 minutes at 100oC. Relative protein 
concentrations were determined using the 660nm Protein Assay Reagent with Ionic 
Detergent Compatibility Reagent (Pierce) to allow equal loading of lysates. Loading 
amounts were normalized to the least concentrated sample. Protein lysates were resolved 
by SDS-PAGE on Novex 4% Tris-Glycine gels (Invitrogen) for 95 minutes at 125V, 
transferred to Invitrolon nitrocellulose membranes (Invitrogen) for 16 hours on ice at 
75mA, and probed with primary and horseradish peroxidase-conjugated secondary 
antibodies. Membranes were blocked and probed in 4% cold water fish skin gelatin 
(Sigma). The primary antibodies used in this study are anti-Ki-67 (MIB-1, Santa Cruz) 






Transfection of overexpression and fusion constructs 
TrueClone MKI67 (transcript variant 1) and NIFK-GFP expression vectors were 
purchased (OriGene). For transient transfection, exponentially growing MCF-10A, DLD-
1, and the derivative knockout cell lines were transfected with 1µg DNA using Fugene6 
Transfection Reagent (Promega) in antibiotic-free growth media. The next day either 
whole-cell protein lysates were prepared as described, scaled for 6-well plates, or pictures 
were taken using fluorescent microscopy. For stable overexpression, the MKI67 
expression vector was transfected in a 3:1 ratio with pcDNA3.1(-) also using Fugene6 
Transfection Reagent, and selection with G418 (Invitrogen) was initiated two days post-
transfection. 
 
Reverse phase protein array (RPPA) 
Parental MCF-10A and the two isogenic knockout clones were grown for three days in 
0.2ng/mL EGF (1% CD serum) media prior to plating. In 6-well plates, the cells were 
then seeded at either 1x105 cells per well and grown for two days in 20ng/mL EGF media 
or 7.5x105 cells per well and arrested for two days in 0ng/mL EGF media. Parental DLD-
1 and the two isogenic knockout clones were seeded at 2.5x105 cells per well and grown 
for two days in standard growth medium. After two days, the 75-85% confluent cells 
were harvested for RPPA lysates using the Lysis Buffer and 4X SDS Sample Buffer 
supplied by the RPPA Core Facility in MD Anderson Cancer Center. Cellular proteins 
were denatured by 1% SDS (with beta-mercaptoethanol) and diluted in five 2-fold serial 
dilutions in dilution buffer (lysis buffer containing 1% SDS). Serial diluted lysates were 
arrayed on nitrocellulose-coated slides (Grace Biolab) by Aushon 2470 Arrayer (Aushon 
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BioSystems). Total 5808 array spots were arranged on each slide including the spots 
corresponding to positive and negative controls prepared from mixed cell lysates or 
dilution buffer, respectively. Each slide was probed with a validated primary antibody 
plus a biotin-conjugated secondary antibody. Only antibodies with a Pearson correlation 
coefficient between RPPA and western blotting of greater than 0.7 were used in reverse 
phase protein array study. Antibodies with a single or dominant band on western blotting 
were further assessed by direct comparison to RPPA using cell lines with differential 
protein expression or modulated with ligands/inhibitors or siRNA for phospho- or 
structural proteins, respectively. The signal obtained was amplified using a Dako 
Cytomation–catalyzed system (Dako) and visualized by DAB colorimetric reaction. The 
slides were scanned, analyzed, and quantified using a customerized-software 
Microvigene (VigeneTech Inc.) to generate spot intensity. Each dilution curve was fitted 
with a logistic model (“Supercurve Fitting” developed by the Department of 
Bioinformatics and Computational Biology in MD Anderson Cancer Center, 
“http://bioinformatics.mdanderson.org/OOMPA”). This fits a single curve using all the 
samples (i.e., dilution series) on a slide with the signal intensity as the response variable 
and the dilution steps are independent variable. The fitted curve is plotted with the signal 
intensities – both observed and fitted - on the y-axis and the log2-concentration of 
proteins on the x-axis for diagnostic purposes. The protein concentrations of each set of 
slides were then normalized by median polish, which was corrected across samples by the 
linear expression values using the median expression levels of all antibody experiments 





Parental DLD-1 cells and two isogenic knockout clones were propagated for three days 
prior to serial dilution and inoculation. For each group, ten 8- to 10-week-old female 
athymic nude mice (Taconic) were injected subcutaneously in the right flank with 200µL 
of 4:1 reduced growth factor Geltrex:HBSS (Invitrogen) mixture containing serial 
dilutions of the parental and derivative DLD-1 cell lines. Tumor volumes were measured 
weekly and calculated by multiplying the length, width, and height of each tumor until 
reaching the upper limit of 1.5cm3. The NIH Guide for the Care and Use of Laboratory 
Animals was followed in all experiments. 
 
Fluorescent in situ hybridization (FISH) 
Exponentially growing cells were dissociated with trypsin and seeded at 3x104 cells per 
well of an 8-chamber culture slide (BD Falcon) in standard growth conditions. After 48 
hours, slides were pretreated using Paraffin Pretreatment Reagent Kits (Abbott) and 
dehydrated with graded ethanol concentrations. Vysis LSI 22 (BCR) SpectrumGreen and 
LSI EGFR SpectrumRed probes were applied to the slide, denatured at 95oC, and 
hybridized overnight at 37oC in a humidity chamber. Slides were then counterstained 
with 4’,6-diamidino-2-phenylindole (DAPI) before allele counting in approximately 200 
cells per probe per clone under fluorescence microscopy. 
 
Flow cytometry 
DLD-1 parental and HomoKO clones were subjected to flow cytometry analysis for the 
expression of CD44 and CD133. Briefly, 2 million cells were harvested from 85% 
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confluent flasks and resuspended in PBS with 0.1% BSA. The cells were washed and 
incubated at 4oC for 15 minutes with anti-CD44-allophycocyanin (APC) (1:20 dilution, 
clone G44-26, BD Biosciences) and anti-CD133-phycoerythrin (PE) (1:20 dilution, clone 
AC133, Miltenyi Biotec) antibodies, or mouse-specific IgG2b ĸ-APC (1:100 dilution, BD 
Biosciences) and IgG1-PE (1:20 dilution, Miltnyi Biotec) antibodies. The cells were then 
washed and resuspended in PBS with 0.1% BSA and 2µg/mL propidium iodide (PI), and 
a FACSCalibur flow cytometer (BD Biosciences) was used for all analyses. The cells 
were first gated on the basis of side-scatter and forward-scatter, followed by the exclusion 
of nonviable (PI-positive) cells. The CD44+ and CD133+ gates were created on the basis 
of cellular staining with the isotype control antibodies (IgG2b ĸ-APC and IgG1-PE, 
respectively).    
 
Overexpression of Ki-67 with constitutive GAPDH promoter at endogenous MKI67 locus 
Vectors and targeted clones were generated as described in the “Targeted knock out of 
MKI67” section, except a minimal CMV or human GAPDH promoter was subcloned into 
the pSEPT vector downstream of the selection cassette but upstream of the 3’ loxP site. 
Cloning and screening primers are listed in Table 1.  
 
Targeted restoration of wild type MKI67 expression by rescue vector 
The vector was designed just like the DOWN knockout vector, as described in the 
“Targeted knock out of MKI67” section. However, the 5’ homology arm was extended to 
restore the deleted portion of exon 2 and the adjacent couple hundred base pairs of 




Ki-67 staining of matched primary and metastatic breast carcinomas 
Ki67 proliferation index was assessed by immunohistochemistry (rabbit monoclonal 
antibody, clone 30-9, catalog number 790-4286, Ventana Medical Systems, Inc.,) on 
tissue microarrays (TMAs) containing 19 pairs of matched primary human invasive 
mammary carcinomas and their subsequent visceral metastases harvested at the time of 
surgery. TMAs contained 5-10 cores per tumor to minimize sampling error. The TMAs 
were labeled by immunohistochemistry for Ki67, and the average proliferation index 
across all cores was calculated for each case in increments of 5% nuclear labeling, from 
0% to 100%. Labeling of benign breast lobules and lymphocytes served as positive 
internal controls.  Ki67 proliferation index was considered to be equivalent in the primary 
and metastasis if the values were the same or within a 5% increment of each other. 
If available, the Ki67 proliferation index for the primary or metastatic tumor as 
reported in the surgical pathology report was also subsequently recorded and compared to 
the result on the TMA to ensure concordance. One case showed marked discordance in 
the Ki67 proliferation index of the primary tumor from the surgical pathology report 
(Ki67 proliferation index of 25-30%) to the TMA value (Ki67 proliferation index of 2%), 
and this case was discarded from evaluation.  
In four cases, the primary tumor Ki67 was unevaluable on the TMA due to 
processing artifact; in these 4 cases, the reported Ki67 proliferation index from the 
surgical pathology report was used for analysis. The remaining 14 cases had concordant 
Ki67 proliferation indices in the primary tumor between the TMA result and the surgical 
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pathology report. Ki67 was rarely performed on the metastatic tumor in the surgical 
pathology report (n=4), but those 4 cases did have concordant values with the TMA. 
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3          Results 
 
Generation of somatic cell Ki-67 knockouts 
We generated isogenic somatic cell knockouts of Ki-67 in both MCF-10A and DLD-1 
cell lines. MCF-10A cells are a non-tumorigenic, spontaneously immortalized, 
genetically stable breast epithelial cell line, whereas DLD-1 cells are a microsatellite 
instable (MIN) colorectal cancer cell line. We used these cell lines primarily because they 
are both diploid for the MKI67 locus and susceptible to gene targeting. An added benefit 
of using MCF-10A cells is that, since they require various exogenous growth factor 
supplementations for growth, the removal of epidermal growth factor (EGF) causes the 
cells to fully arrest. 
The targeting vectors were constructed to insert premature nonsense (STOP) 
mutations into the first coding exon (exon 2) of the MKI67 gene, which would disrupt 
each open reading frame. Targeted integration of the 11-base pair STOP sequence is 
achieved via homologous recombination of the transduced targeting vector with the 
MKI67 gene locus. By subsequently introducing Cre recombinase transiently, all 
exogenous bacterial sequences originating from the targeting vector were removed except 
for the STOP sequence and a 117-base pair sequence surrounding a loxP site in intron 2. 
For both MCF-10A and DLD-1 cell lines, we established two independently derived Ki-
67 knockout clones. 
Since these cell lines are diploid for the MKI67 locus, two successive rounds of 
gene targeting were required to generate a full knockout. The transduction of the parental 
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cell line with a targeting vector will yield a heterozygous knockout (HetKO), and the 
subsequent transduction of the HetKO should yield a homozygous knockout (HomoKO). 
However, as we have observed across numerous gene-targeting projects in our lab, the 
use of only one targeting vector will predominantly result in re-targeting of the first 
targeted allele in the HetKO, making it quite difficult to isolate a HomoKO clone. We 
therefore designed a system utilizing two targeting vectors that would eliminate the 
possibility of re-targeting upon the second transduction. To control for mutation location, 
the two vectors shared the same 5’ homology arm and adjoining STOP sequence but 
contained different 3’ homology arms. The 3’ homology arm of the “UP” vector targeted 
a region of intron 2 that resulted in the deletion of 13-base pairs of genomic sequence 
upon successful recombination. The “DOWN” vector 3’ homology arm, on the other 
hand, targeted a region containing exons 2 and 3 that resulted in the deletion of 1,416-
base pairs of genomic sequence, including the genomic region corresponding to the “UP” 
vector 3’ homology arm (Figure 1A-B). Therefore, utilizing the “UP” vector for the 
second round of gene targeting resulted in homologous recombination only with the 
remaining wild type allele, eliminating excess screening of re-targeted clones. Correct 
targeting was demonstrated by PCR amplification of gDNA derived from Ki-67 knockout 
clones after Cre-loxP recombination (Figure 2). 
When generating HetKO clones from parental MCF-10A or DLD-1 cell lines, we 
calculated a targeting frequency of roughly 4%, regardless of which vector was used. For 
the subsequent transduction of the appropriate HetKO clone in generating a HomoKO 
clone, we would expect to see a targeting frequency of about 2% since only one wild type 
allele remains. In actuality, we observe a 1.5% targeting frequency. The difference 
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between the observed and theoretical values could be due to the inability to distinguish 
between primary targeted cells from daughter cells of those original clones during the 
selection and screening process. Regardless, targeting frequencies even 10- to 100-fold 
less would still indicate a real, non-artifactual event. In the instance of attempting to 
knockout a gene essential to the viability of the cell, you could expect to see rare re-
targeting events, of which we detected none, and a 0% targeting efficiency. Therefore, 
these independently generated HomoKO clones are true isogenic Ki-67 knockout cell 
lines. 
We first tried to verify the knockout of Ki-67 through quantitative real-time RT-
PCR (qRT-PCR) mRNA expression analysis. The premature nonsense mutations we 
incorporated into the first coding exon should result in elimination of those mutant 
mRNA molecules through the nonsense-mediated decay (NMD) pathway [77]. 
Therefore, we would expect to see a “full” amount of MKI67 mRNA in the parental cell 
lines, about half of the “full” transcript levels in the HetKO clones, and almost no 
transcript in the HomoKO clones. Interestingly, the resulting levels of detectable MKI67 
transcript by qRT-PCR varied depending upon growth conditions. For instance, when the 
isogenic cell lines were growth arrested (MCF-10A) or serum starved (DLD-1) for two 
days and then grown under standard conditions for one day, we observed our expected 
results. However, if the cells were continually grown under standard conditions for 
multiple passages before harvesting for qRT-PCR analysis, the MKI67 transcript levels 
reached a steady-state amount that was equivalent for all clones (data not shown). 
Although the various growth conditions confounded our results, the observed NMD in 
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growth arrested and serum starved conditions led us to believe that we had properly 
knocked-out Ki-67.  
MCF-10A cells and the derivative knockouts, propagated in either standard 
growth (20ng/mL EGF, 5% HS) or growth arrest (0ng/mL EGF, 1% CD serum) media 
conditions, were processed to resemble tissue blocks by paraffin-embedding agarose 
plugs of the cells, which were subsequently labeled with a Ki-67 antibody via IHC. 
Under standard growth conditions, Ki-67 protein levels in the heterozygous knockout 
(HetKO) clones were unchanged relative to the parental cell line, whereas the 
homozygous knockout clone (HomoKO) showed a clear lack of Ki-67 protein with only 
trace amounts of residual, non-specific staining. Since Ki-67 protein is not present in 
quiescent cells and has such a short half-life, the trace staining evident in the clones 
propagated in growth arrest conditions indicates that the samples contain artifactual 
staining (Supplement 1). Western blot analysis confirmed the IHC results, establishing 
that Ki-67 protein levels remain largely unchanged in the HetKOs relative to the parental 
cell line whereas protein expression is completely ablated in the HomoKOs, which could 
be restored by transient transfection of the HomoKO clones with a Ki-67 (transcript 
variant 1) over-expression vector (Figure 2).  
 
Loss of Ki-67 does not significantly change protein expression patterns or increase 
chromosomal instability 
Although the known interactions of Ki-67 are limited, we wanted to ascertain a sense of 
the global effects from the knock out of Ki-67, particularly on downstream effectors. We 
performed reverse phase protein assays (RPPA) on the isogenic MCF-10A and DLD-1 
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clones to identify any major changes in protein expression between the parent and 
HomoKO clones (Supplement 2). While some genes did show significantly altered 
expression, it was not consistent across both MCF-10A and DLD-1 cell lines, leading us 
to believe that the differences are likely due to clonal variability. Similarly, if Ki-67 is 
indeed responsible for cell proliferation as many hypothesize, we would expect to see the 
MCF-10A HomoKO clones grown in Full EGF conditions to have a similar gene 
expression signature as the parental cell line growth arrested in No EGF conditions. 
However, this trend is not observed. The only significant differences detected were 
between growth conditions and cell type. Therefore, we conclude that the loss of Ki-67 
does not significantly affect the expression of many of the well-known effectors from 
various signaling pathways. 
We also eliminated the possibility that the loss of Ki-67 affects paracrine 
signaling after finding that growing the HomoKO clones in conditioned media from the 
respective parental cell line did not rescue the growth phenotype (Supplement 3). 
However, the conditioned media did cause the HomoKO colonies to morphologically 
resemble the parental cells grown under normal media conditions even though when 
grown in monolayers, the parental and HomoKO cells displayed no morphological 
differences. Also, since other studies have linked Ki-67 to higher-order chromatin 
structure [14, 32, 37] and DNA damage response (outside discussions), we wanted to 
determine whether the loss of Ki-67 could cause chromosome instability. Using FISH 





Effect of Ki-67 knock out on proliferative and clonogenic potential in vitro 
It has been reported that knock down of MKI67 results in decreased cell proliferation and 
increased apoptosis [50, 55, 56]. We performed 7-day growth assays comparing the 
proliferative potential of the parental, HetKO, and HomoKO clones of MCF-10A and 
DLD-1. For the MCF-10A clones, there was no significant difference in growth between 
any of the clones, but we did observe a marginal significant difference for the DLD-1 
parental cell line compared to the HetKO and HomoKO clones (p < 0.05, Figure 3A-C). 
Therefore, knockout of Ki-67 displayed no obvious growth inhibitory effects on either 
MCF-10A or DLD-1 cells.  
 Since the aforementioned growth assays were performed in 96-well plates, we 
wanted to assess whether seeding density affected the observed growth rates. Using the 
same number of cells (1x103), we conducted the assays in plates with increasingly larger 
wells, thereby incrementally decreasing the seeding density. To demonstrate the growth 
phenotype of the cells under normal propagation conditions, we also seeded 6-well plates 
with 1:10 dilutions of 70% confluent plates. Interestingly for both the MCF-10A and 
DLD-1 cells, there was a significant reduction in growth potential of the independent 
HomoKO clones compared to the respective parental cell line as the seeding density 
decreased, although the growth rate appears equivalent under typical cell passage 
conditions as the 96-well growth experiment indicated (Figure 3D). This suggests that 
the absence of Ki-67 causes either reduced proliferative and/or clonogenic potential 
under sparsely seeded conditions. To clarify which process is being affected by the loss 
of Ki-67, we seeded five 96-well plates per cell line with a calculated density of 0.5 cells 
per well, allowing us to count single cell colony growth per plate. For both the MCF-10A 
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and DLD-1 cells, the HomoKO clones contained the same number of colonies as the 
parental cell line but were noticeably smaller in colony size. In fact, the parental cell lines 
contained countable colonies about two weeks before the HomoKO cells formed colonies 
large enough to analyze (data not shown). 
 
Effect of Ki-67 knockout on clonogenic potential in vivo 
While the knockout of Ki-67 significantly reduces the proliferative and/or clonogenic 
potential of MCF-10A and DLD-1 cells when assessed by in vitro colony formation 
assays, we wanted to determine if the effects were observed in vivo as well. Since MCF-
10A cells are a non-tumorigenic breast epithelial cell line, only the DLD-1 clones could 
be used for in vivo experiments. Four 10-fold serial dilutions (106 – 103 cells) of each 
DLD-1 clone were injected subcutaneously into athymic nude mice, and the subsequent 
tumors were allowed to grow until reaching a maximum volume of 1.5cm3. Similar to the 
in vitro clonogenic assays, the overall growth rate of the HomoKO tumors was 
significantly less than that of the parental tumors, as shown by comparing the tumor 
volumes of the three clones of the same dilution (Figure 4A). Moreover, when 
comparing tumor volumes of the four serial dilutions of the same clone, the reduced 
clonogenic potential of the HomoKO clones is noticeable, demonstrated by the decrease 
in tumor formation for all dilutions other than the 106 group compared to the parental cell 






Stem cell markers and chemotherapy sensitivity 
The cancer stem cell (CSC) hypothesis postulates that there is a hierarchical organization 
of cells within a tumor, an intrinsic heterogeneity, such that a specific subpopulation is 
responsible for tumorigenesis and metastasis [78, 79]. CSCs have been defined and 
isolated by a series of cell surface markers whose expression pattern is unique to each 
tumor type. For colorectal CSCs, identification remains controversial due to the lack of 
consensus for molecular markers even though multiple have been proposed. However, 
the markers most commonly used to identify and isolate colorectal CSCs are CD133 and 
CD44. According to one group, subcutaneous injections of CD133+CD44+ cells always 
form xenografts [80], and high levels of double-positive cells were a strong indicator for 
worse disease-free survival and increased risk of recurrence when identified in primary 
tumors [81]. In another study, CD133+CD44+ cells were present in each liver metastasis 
while the primary tumors contained cells with variable expression levels [82]. Via flow 
cytometry, we analyzed the isogenic DLD-1 HomoKO cell lines for their pattern of 
CD133 and CD44 expression. We found 0.86% of the parental DLD-1 cells to be 
CD133+CD44+, yet the percentage of double-positive HomoKO cell lines was reduced to 
0.20% and 0.165%, respectively (Figure 5). This could indicate that the loss of Ki-67 
negatively affects the number or quality of CSCs in a population. 
Various studies have shown CSCs to be resistant to numerous anti-neoplastic 
agents, implicating that small population of cells in tumor relapse after therapy [83, 84]. 
Therefore, much clinical interest lay in the potential to target CSC. In the same vein, as a 
single gene predictor for response to chemotherapies, Ki-67 expression remains 
controversial albeit promising; but in the multi-gene setting of the Oncotype DX breast 
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and colon cancer assays, it has proven to be both prognostic and predictive [57, 62, 71, 
85]. Since the knock out of Ki-67 in DLD-1 cells resulted in a reduction of 
CD133+CD44+ subpopulation of CSCs, we wanted to assess whether the HomoKO cells 
displayed altered sensitivities to various classes of chemotherapies. Paclitaxel 
(microtubule stabilizer), cisplatin (alkylating agent), doxorubicin (DNA intercalator), and 
5-fluorouracil (anti-metabolite) were all used at doses that inhibited the growth of the 
MCF-10A and DLD-1 parental cell lines by about 50% (IC50) over seven days, which 
would serve as a control for chemotherapeutic activity. Compared to parental MCF-10A 
cells, the HomoKO clones did not display any significant differences in growth following 
exposure to each of the aforementioned chemotherapies. On the other hand, the DLD-1 
HomoKOs showed a significant increase in sensitivity to each of the chemotherapies 
compared to the parental cells (Figure 6). This decreased resistance to chemotherapies 
correlates with the decreased number or quality of CSCs in the population. 
 
Failed overexpression of Ki-67 transgene 
Since we were able to successfully use a Ki-67 overexpression vector, pCMV6-XL4-
Ki67 purchased from OriGene (Supplement 5), to transiently transfect MCF-10A and 
DLD-1 HomoKO clones and restore wild type Ki-67 protein, we wanted to stably 
overexpress Ki-67 and determine if we can rescue the reduced proliferative and/or 
clonogenic potential. Since the overexpression vector did not contain a selection marker, 
we performed a co-transfection with the pcDNA3.1(-) construct, which would confer 
resistance to neomycin. Using standard transfection protocols for the Fugene 6 
transfection reagent, the total quantity of pCMV6-XL4-Ki67 transfected into MCF-10A 
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and DLD-1 HomoKO cells was anywhere from 3x – 5x the amount of pcDNA3.1(-), thus 
ensuring any resistant cells would also likely contain the overexpression vector as well 
based upon Poisson distribution. However, after weeks of selection, we could not detect 
Ki-67 overexpression in any of the stably resistant clones that resulted.  
 
Knock in of constitutive promoter at endogenous MKI67 locus to overcome growth arrest 
To determine whether Ki-67 plays a role in driving cell proliferation, we attempted to 
knock in a constitutive promoter at the endogenous MKI67 locus that would express 
MKI67 even under conditions of growth arrest when Ki-67 protein is typically absent. 
The targeting vectors were designed much like the knockout constructs in that two 
homology arms, which direct the vector to the genomic region of interest, flank loxP sites 
that sit on either end of a neomycin selection cassette. However, between the selection 
cassette and downstream loxP site, we cloned in either a minimal CMV or human 
GAPDH promoter. The vector was designed to target the 5’UTR region of the MKI67 
gene so that the selection cassette was driven from the endogenous promoter, yet the 
constitutive CMV or GAPDH promoter would drive expression of the MKI67 coding 
region (Supplement 6).  
 Based upon mRNA expression analysis through qRT-PCR, we found that MCF-
10A cells containing the GAPDH knock in promoter and propagated under growth 
arresting conditions (0ng/mL EGF) express equivalent levels of mRNA as parental cells 
grown under physiologic EGF conditions (0.2ng/mL EGF). However, when clonogenic 
assays were performed using the parental and knockin cells under growth arrest 
conditions, the knockin cells did not overcome growth arrest to form colonies (data not 
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shown). Therefore, based on these results, we can conclude that Ki-67 does not drive cell 
proliferation by itself. One caveat to these experiments is that we were only able to 
generate one knockin clone, so we were not able to reproduce the result in independently 
derived clones. 
 
Rescue of Ki-67 expression in knockout cells by re-targeting mutant allele with vector 
that restores coding genomic sequences 
We designed another gene targeting vector with only a slight modification compared to 
the original Ki-67 knockout constructs. This rescue vector was created to re-target one of 
the already targeted and knocked-out MKI67 alleles, replacing the STOP sequences with 
the original exonic sequence that had been deleted and restoring the full length 
expression of Ki-67. The same homology arms as the “DOWN” knockout vector were 
utilized, except the 5’ homology arm now excludes the STOP mutations and includes all 
of exon 2 and a couple hundred base pairs of the downstream intronic sequence, thus 
ensuring restoration of all necessary coding and splicing sequences (Supplement 7A). 
We were able to successfully homologously integrate the rescue vector into the “UP” 
vector-targeted allele and restore a wild type Ki-67 expression, which we confirmed both 
by PCR and western blot for multiple isolated clones (Supplement 7B). However, when 
we performed clonogenic assays comparing the rescued clones to the parental and 
HomoKO cell lines, we were met with ambiguous results. Some of the clones showed a 
moderately restored proliferative and clonogenic phenotype while others behaved similar 




Transiently transfected NIFK-GFP does not display aberrant cellular localization. 
Through its FHA domain, it has been shown that Ki-67 interacts with at least two 
proteins: Hklp2 and NIFK. Using a purchased NIFK-GFP fusion construct (OriGene), we 
transfected MCF-10A and DLD-1 parental and HomoKO cell lines and observed 
localization patterns. Although we expected to see aberrant localization of NIFK in the 
Ki-67 knockout clones, there were no obvious differences between the parental and 
HomoKO cell lines (data not shown). 
 
Change in Ki-67 expression between matched primary and metastatic breast carcinomas 
The primary breast carcinomas (n=18) consisted of 17 invasive ductal carcinomas and 1 
invasive lobular carcinoma; 5 Elston grade 2 and 13 Elston grade 3; and 11 luminal A 
phenotype (ER+/PR+/Her2-), 1 Her2 phenotype (ER-/PR-/Her2+) and 6 triple negative 
(ER-/PR-/Her2-). The metastatic sites (one per patient) consisted of 8 brain, 5 lung, 2 
liver, 2 gastrointestinal tract, and 1 paraspinal soft tissue. 
The Ki67 proliferation indices were the same in the primary and metastasis in 
77% (14/18) cases. The Ki67 proliferation indices were increased in the metastatic site in 
22% (4/18) of matched cases. All cases showed an increase in the Ki67 proliferation 
index by an increment of greater than 20% (Table 2). The cases with increased Ki67 in 
the metastasis were all invasive ductal carcinomas; 2 metastasized to the lung and 2 to the 
brain; 1 was Her2 phenotype, 2 triple negative phenotype, and 1 luminal phenotype. In 
total, an increase in Ki67 in the metastasis was seen in 100% (1/1) Her2 cases, 33% (2/6) 
triple negative cases, and 9% (1/11) luminal cases; and in 40% (2/5) lung metastases,25% 
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(2/8 brain metastases, and none of the remaining metastatic sites (liver, gastrointestinal 
















































































































































































Since cancer is a disease of uncontrolled cell growth, it is logical to investigate and 
attempt to therapeutically target Ki-67, a protein that has been widely accepted as the 
histological marker for proliferation since its discovery. However, the paucity of 
knowledge regarding Ki-67 makes it difficult to validate as a drug target. This 
information gap is primarily due to the difficulty of working with a high molecular 
weight and highly proteolytically susceptible protein in vitro. There is also a surprising 
lack of functional genomic studies, which may well be the result of conventional wisdom 
that Ki-67 is essential for the viability of the cell. With our expertise in somatic cell gene 
targeting, we wanted to overcome the limitations of the few RNAi studies by creating 
knockout cell lines that completely ablated all functional Ki-67 protein and assess the 
effects on various cellular processes.  
 Even though previous functional genomic studies put into doubt the likelihood of 
creating Ki-67 knockout cell lines, predicting it would result in a lethal phenotype, we 
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were in fact able to generate both heterozygous (HetKO) and homozygous (HomoKO) 
Ki-67 knockout somatic cells in MCF-10A and DLD-1 cell lines. Although gene 
targeting accounts for the questions of specificity and knockdown levels in RNAi studies, 
the technique is not without its own caveats. Since almost all genes are too large to 
completely knockout, only select exons are deleted or mutated to incorporate premature 
nonsense mutations. While this leaves open the possibility for the presence of truncated 
proteins, great care is normally taken to adequately remove functional domains while 
nonsense-mediated decay (NMD) typically eliminates the aberrant mRNAs before they 
can be translated into protein. Through rigorous sequencing, PCR screening, western blot 
analysis, and IHC, we can definitively confirm that our HomoKO clones lack full length 
Ki-67. Regardless, there remains the chance, however unlikely, that a truncated form of 
Ki-67, re-initiated from exon 7 or another downstream exon, escaped our best efforts to 
eliminate all functional protein.  
As mentioned above, we meticulously examined whether we did in fact 
completely knockout Ki-67 and whether the observed phenotype was not an artifactual 
result. First, in generating the clones, we calculated about a 9% targeting frequency upon 
the transduction of the first vector in MCF-10A cells and a 12% targeting frequency in 
DLD-1 cell lines. If the cells were truly diploid for the MKI67 gene and only one allele 
was targeted, we could expect a 50% reduction in targeting frequency upon transduction 
of the second vector to create the full knockout. In practice, we observed a targeting 
frequency of 4% in the MCF-10A cells and a 5% targeting frequency in the DLD-1 cells, 
which gives us considerable confidence that both alleles were properly targeted and 
knocked out. Both percentages are likely inflated due to our inability to discern between 
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primarily targeted clones and daughter cells of those primary clones and, therefore, are 
likely closer to a 2:1 ratio than we observed. 
 Again, the majority of research conducted on Ki-67 has focused on its temporal 
and spatial expression patterns. Other areas of interest, such as structure, molecular 
interactions, and cellular function, have not been explored in any detail. When comparing 
isogenic knockout cell lines, this lack of information makes it difficult to interrogate very 
specific areas of interest, such as effects on various signaling networks, leading to more 
global questions. For instance, we performed RPPA using a panel of over 150 validated 
antibodies for commonly studied genes. When comparing gene expression changes 
between the parent and HomoKO cells, we did not observe common trends to both MCF-
10A and DLD-1 cell lines. Although the cell line specific expression alterations should be 
investigated further, it is beyond the scope of this study. Similarly, since Ki-67 has been 
implicated in higher order chromatin structure and potentially the DNA damage response, 
we used FISH to assess whether loss of Ki-67 affected chromosome stability, which it 
definitively did not. While this indicates that Ki-67 likely does not play a role in genomic 
stability, further research is required to fully understand the role of Ki-67 in chromatin 
structure and response to DNA damage. 
 Given the widespread use of Ki-67 as a histological marker for the growing 
fraction of cells in histopathological samples, the aforementioned RNAi studies 
attempted to determine if growth arrest or cell death resulted from loss of Ki-67. 
Likewise, we performed similar growth experiments but came to the opposite conclusion: 
loss of Ki-67 does not affect the proliferative potential of cells plated for monolayer 
growth. We did notice a significant difference in growth potential, however, when cells 
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were plated sparsely for colony formation. Unlike the MCF-10A and DLD-1 isogenic 
clones grown in monolayer, the HomoKO clones formed colonies at a much slower rate 
than the parental cell lines. However, the MCF-10A clones still formed the same number 
of colonies, only at a reduced rate of proliferation. On the other hand, it seems both the 
proliferative and clonogenic potential of the DLD-1 HomoKO clones was reduced. When 
we used the DLD-1 isogenic clones to form xenografts of serial dilutions, we observed 
the same trend. The HomoKO clones formed tumors at a slower rate, but the lower 
dilutions also seemed to have a reduced clonogenic potential.  
We also attempted three different methods to either over express or restore wild 
type expression of Ki-67. First we tried to stably transfect a Ki-67 transgene into both 
MCF-10A and DLD-1 HomoKO cells. However, likely due to the large size of the 
transgene, we were not able to isolate any overexpression clones. Next, through gene 
targeting, we wanted to insert a constitutive promoter at the MKI67 locus that would 
drive expression of the gene. The targeting vector would homologously recombine 
downstream of the endogenous promoter but upstream of the first coding exon, allowing 
antibiotic selection to be driven from the MKI67 promoter while MKI67 expression was 
controlled by the integrated CMV or human GAPDH promoter. While we were able to 
effectively target the locus and isolate targeted clones, the expression level of Ki-67 was 
not as high as we had expected. In fact, when the targeted clones were propagated under 
growth arrest conditions, the level of Ki-67 expression was equivalent to cells grown 
under physiologic EGF concentration (0.2ng/mL). This amount of Ki-67 expression was 
apparently not enough to overcome growth arrest and drive proliferation. Further to that 
point, when the targeted clones were grown under standard growth conditions (20ng/mL 
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EGF), the expression level of Ki-67 was half the amount observed in parental MCF-10 
and DLD-1 cells grown under the same conditions. So while the targeted integration of a 
constitutive promoter at the MKI67 locus did show some low level expression, the clones 
more closely resembled HetKOs phenotypically rather than overexpression clones. And, 
lastly, we tried to restore wild type expression of one allele in the HomoKO clones 
through another round of gene targeting. The rescue vector targeted the same genomic 
region as the DOWN knockout vector, and the only variation between the two vectors is 
the 5’HA. While the DOWN knockout vector 5’HA contained the three STOP mutations, 
the new rescue vector incorporated the deleted region of exon 2 and the adjacent intronic 
sequence. Although we were successful in restoring wild type Ki-67 protein expression, 
we were not able to demonstrate a rescued clonogenic phenotype. Some of the isolated 
clones displayed increased clonogenic potential, approaching the clonogenic capability of 
parental cells, while others still behaved as the HomoKO cells.   
The cancer stem cell (CSC) theory postulates that CSCs are a subset of cells that 
have the ability to both self-renew and maintain the tumor by giving rise to differentiated, 
heterogeneous, non-tumorigenic cells that comprise the bulk of the tumor [78, 79]. Only 
CSCs can maintain tumor growth indefinitely because, although the non-stem cells can 
actively grow and proliferate, they are destined to die. The initial gold standard for 
determining the stemness of CSCs was through serial transplantations of small numbers 
of cells into immunocompromised mice to assess the ability to self-renew and form 
tumors [86]. Therefore, we questioned whether the reduced clonogenic potential of DLD-
1 HomoKO clones could result from the loss of Ki-67 affecting the stem-like nature of 
the cells. To complement transplantation assays, CSCs have been defined and isolated by 
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a series of cell surface markers whose expression pattern is unique to each tumor type. 
For colorectal CSCs, identification remains controversial due to the lack of consensus for 
molecular markers even though multiple have been proposed. However, the markers most 
commonly used to identify and isolate colorectal CSCs are CD133 and CD44. Upon 
subcutaneous injection, CD133+CD44+ cells always form xenografts [80], and high levels 
of double-positive cells were a strong indicator for worse disease-free survival and 
increased risk of recurrence when identified in primary tumors [81]. In another study, 
CD133+CD44+ cells were present in each liver metastasis while the primary tumors 
contained cells with variable expression levels [82]. When we analyzed the parental and 
HomoKO clones via flow cytometry, there was a noticeable decrease in the percentage of 
CD133+CD44+ HomoKO cells. This loss of stemness in the HomoKO clones could 
explain their reduced clonogenic potential. According to our results, it seems like the loss 
of Ki-67 somehow affects the CSC population. 
It has also been reported that CSCs are more resistant to chemotherapy and/or 
radiotherapy [83, 87]. While these standard treatments are quite useful at reducing tumor 
bulk, patients ultimately experience recurrence when deployed as monotherapies. The 
prevailing theory is that CSCs are resistant to these therapies via drug efflux pumps, 
alcohol dehydrogenase (ALDH) activity, upregulated anti-apoptotic machinery, and 
enhanced DNA damage response, thus allowing repopulation of the tumor [88, 89]. Since 
our analysis of the CSC population in the isogenic DLD-1 Ki-67 knockout clones 
revealed that loss of Ki-67 is somehow affecting the CSC population, we wanted to 
confirm this data with a completely separate experiment. Given the known resistance of 
CSCs to chemotherapy, we hypothesized that perhaps if loss of Ki-67 is affecting the 
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CSC population then perhaps loss of Ki-67 will affect the sensitivity of the DLD-1 cells 
to chemotherapy. In this study, when we exposed the DLD-1 isogenic clones to various 
chemotherapies, the HomoKO clones showed increased sensitivity to the drugs. While 
this seems to run counter to the clinical model that increased Ki-67 staining predicts for 
better response to chemotherapy, it has the potential to be a significant finding in the 
battle against metastatic disease. Combined with the already-reduced tumorigenic 
potential of Ki-67 knockout cells, treatment with chemotherapy or radiation should 
hopefully destroy the CSCs along with the bulk of the tumor, significantly inhibiting the 
ability of the cancer to metastasize. 
A study was published last year that examined Ki-67 expression in breast cancer 
patients pre- and post-neoadjuvant chemotherapy [90]. The authors conclude that it is the 
final amount of Ki-67 expression in the residual disease that dictates prognoses for the 
patients. However, in looking at their data, we interpret their results somewhat 
differently. Since patients who has the highest level of Ki-67 expression to start but were 
reduced to a “low” level after therapy fared better in disease-free survival compared to 
patients who actually had “low/intermediate” Ki-67 expression to start and were reduced 
to “low” levels, we believe that it is the overall change in Ki-67 expression from baseline 
that should guide prognosis. Given this new understanding, we wondered if patients who 
have metastatic disease, often considered a “bad” prognosis, would display increased 
levels of Ki-67 staining in the metastatic tumor relative to their primary site, correlating 
with the bad prognosis. We were able to stain and score 18 matched primary and 
metastatic invasive breast carcinomas for Ki-67 expression. In all of the cases, the 
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metastatic site showed either an increase or no change in Ki-67 staining, confirming that 
prognostic power of the change in Ki-67 expression post-therapy. 
Although we demonstrated that loss of Ki-67 has no effect on cell growth in a 
bulk population of cells, calling into question it validity as a drug target, the reduced 
clonogenicity in vitro and in vivo establishes the possibility that Ki-67 could be a very 
useful therapeutic target, specifically at the micrometastatic level. While numerous 
studies have shown that Ki-67 can be used as a prognostic marker in a variety of contexts 
[57, 60, 61, 63], only a couple examined the Ki-67 status of metastatic specimens 
compared to the primary tumors [91, 92]. They showed that increased expression of Ki-
67 at the metastatic site, relative to the primary tumor, correlated with decreased disease-
free survival. Since most cancer deaths result from metastatic disease, validating how 
therapeutic inhibition of Ki-67 could reduce the rate or likelihood of metastasis has the 
potential to be a very impactful finding. Ki-67 is still useful as a marker for cell 
proliferation, and a prognostic and predictive indicator in the clinical setting, but its true 
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